C1-Esterase Inhibitor: An Anti-inflammatory Agent And Its Potential ...
The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation- Clipboard
- My Bibliography
- Collections
- Citation manager
Save citation to file
Format: Summary (text) PubMed PMID Abstract (text) CSV Create file CancelEmail citation
Email address has not been verified. Go to My NCBI account settings to confirm your email and then refresh this page. To: Subject: Body: Format: Summary Summary (text) Abstract Abstract (text) MeSH and other data Send email CancelAdd to Collections
- Create a new collection
- Add to an existing collection
Add to My Bibliography
- My Bibliography
Your saved search
Name of saved search: Search terms: Test search terms Would you like email updates of new search results? Saved Search Alert Radio Buttons- Yes
- No
Create a file for external citation management software
Create file CancelYour RSS Feed
Name of RSS Feed: Number of items displayed: 5 10 15 20 50 100 Create RSS Cancel RSS Link CopyActions
CiteCollectionsAdd to Collections- Create a new collection
- Add to an existing collection
Page navigation
- Title & authors
- Abstract
- Publication types
- MeSH terms
- Substances
- LinkOut - more resources
Abstract
C1-esterase inhibitor (C1-Inh) therapy was introduced in clinical medicine about 25 years ago as a replacement therapy for patients with hereditary angioedema caused by a deficiency of C1-Inh. There is now accumulating evidence, obtained from studies in animals and observations in patients, that administration of C1-Inh may have a beneficial effect as well in other clinical conditions such as sepsis, cytokine-induced vascular leak syndrome, acute myocardial infarction, or other diseases. Activation of the complement system, the contact activation system, and the coagulation system has been observed in these diseases. A typical feature of the contact and complement system is that on activation they give rise to vasoactive peptides such as bradykinin or the anaphylatoxins, which in part explains the proinflammatory effects of either system. C1-Inh, belonging to the superfamily of serine proteinase inhibitors (serpins), is a major inhibitor of the classical complement pathway, the contact activation system, and the intrinsic pathway of coagulation, respectively. It is, therefore, endowed with anti-inflammatory properties. However, inactivation of C1-Inh occurs locally in inflamed tissues by proteolytic enzymes (e.g., elastase) released from activated neutrophils or bacteria thereby leading to increased local activation of the various host defense systems. Here we will give an overview on the biochemistry and biology of C1-Inh. We will discuss studies addressing therapeutic administration of C1-Inh in experimental and clinical conditions. Finally, we will provide an explanation for the therapeutic benefit of C1-Inh in so many different diseases.
PubMed Disclaimer
Publication types
- Research Support, Non-U.S. Gov't Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Review Actions
- Search in PubMed
- Search in MeSH
- Add to Search
MeSH terms
- Animals Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Anti-Inflammatory Agents, Non-Steroidal / therapeutic use* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C1 Inactivator Proteins / physiology Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C1 Inactivator Proteins / therapeutic use* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C1 Inhibitor Protein Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Glycosaminoglycans / metabolism Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Humans Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Inflammation / drug therapy* Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Leukocytes / drug effects Actions
- Search in PubMed
- Search in MeSH
- Add to Search
Substances
- Anti-Inflammatory Agents, Non-Steroidal Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C1 Inactivator Proteins Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Complement C1 Inhibitor Protein Actions
- Search in PubMed
- Search in MeSH
- Add to Search
- Glycosaminoglycans Actions
- Search in PubMed
- Search in MeSH
- Add to Search
LinkOut - more resources
Other Literature Sources
- The Lens - Patent Citations Database
- Clipboard
- Save
- My Bibliography
- Collections
- Citation Manager
NCBI Literature Resources
MeSH PMC Bookshelf Disclaimer
The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.
Từ khóa » C1 Inhibitör
-
C1-inhibitor - Wikipedia
-
C1 İnhibitör Nedir? Eksikliğinde Neden Anjioödem Gelişir? | Makale
-
Hereditary C1 Esterase Inhibitor Deficiency - Dysfunctional Factor
-
5709 C1 İNHİBİTÖR | Caleffi Türkiye
-
[PDF] AİLEVİ AKDENİZ ATEŞLİ BİR OLGUDA C1 ... - Gazi Medical Journal
-
[PDF] The Attack Localizations In C1 Inhibitor Deficient Hereditary ...
-
Opinions Of Turkish Hereditary Angioedema Patients Regarding The ...
-
Complement C1 Esterase Inhibitor [Mass/volume] In Serum Or Plasma
-
Herediter Anjioödem - Cengiz Kırmaz